Holen Sie sich die Stockscreener-App
1.945
9.27%
0.165
Schlusskurs vom Vortag:
$1.78
Offen:
$1.82
24-Stunden-Volumen:
1.66M
Relative Volume:
2.07
Marktkapitalisierung:
$132.64M
Einnahmen:
$593.00K
Nettoeinkommen (Verlust:
$-45.85M
KGV:
-2.8332
EPS:
-0.6865
Netto-Cashflow:
$-37.97M
1W Leistung:
+10.51%
1M Leistung:
+13.08%
6M Leistung:
-16.88%
1J Leistung:
-35.81%
1-Tages-Spanne:
$1.81
$2.00
1-Wochen-Bereich:
$1.68
$2.00
52-Wochen-Spanne:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.94 | 121.70M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Eingeleitet | Noble Capital Markets | Outperform |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
CRDF Technical Analysis | Trend, Signals & Chart Patterns | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Is Cardiff Oncology (CRDF) 5.1% Undervalued After Q1 2026 Earnin - GuruFocus
A Quick Look at Today's Ratings for Cardiff Oncology(CRDF.US), With a Forecast Between $6 to $10 - Moomoo
Cardiff Oncology (CRDF) Reports Positive Trial Data and Leadersh - GuruFocus
Cardiff Oncology (CRDF) Secures Funding Through 1Q27 - GuruFocus
Cardiff Oncology Q1 net loss narrows as operating expenses fall - TradingView
Cardiff Oncology earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology: Q1 Earnings Snapshot - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) details Q1 2026 loss and Phase 3 plans - Stock Titan
FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) posts Q1 loss, warns on cash and details onvansertib data - Stock Titan
Cardiff Oncology, Inc.Common Stock (NQ: CRDF - FinancialContent
CRDF Stock Price, Quote & Chart | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
TradingKey - TradingKey
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
Cardiff Oncology (CRDF) to Release Earnings on Thursday - MarketBeat
MSN Money - MSN
Cardiff Oncology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
CRDF Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
[Form 4] Cardiff Oncology, Inc. Insider Trading Activity - Stock Titan
Cardiff Oncology (CRDF) COO Ajay Aggarwal submits initial insider ownership - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity - GlobeNewswire
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology slumps after leadership shakeup - MSN
[ARS] Cardiff Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement - Stock Titan
CRDF Q1'26 Earnings: revenue estimate is 88.57K USD - TradingView
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cardiff Oncology Inc-Aktie (CRDF) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):